VPIX Medical, Inc.

Based in Daejeon, South Korea, VPIX Medical, Inc. develops advanced medical technology solutions, focusing on real-time digital biopsy systems and clinical imaging for cancer surgeries, enhancing tissue diagnosis accuracy and surgical efficiency. Founded in 2016, VPIX Medical, Inc. specializes in medical technology solutions.

The company has raised KRW 9. 5 billion in its latest funding round on August 26, 2025, from investors including Hana Ventures and KDB Capital. It operates primarily out of Daejeon, South Korea, serving healthcare institutions involved in oncology. VPIX Medical focuses on providing innovative medical technology solutions, primarily through its flagship product, the cCeLL platform, which serves as a real-time digital biopsy system designed for intraoperative consultations during cancer surgeries.

The platform enhances the accuracy and efficiency of tissue diagnoses, enabling surgeons to make informed decisions during surgical procedures. VPIX Medical also offers a comprehensive suite of clinical imaging solutions tailored to various organs, including the brain, breast, lung, stomach, pancreas, large intestine, kidney, and prostate. The company’s products cater to hospitals and medical institutions engaged in oncology, with a client base that includes prominent healthcare providers such as Samsung Medical Center and 고려대학교 안암병원. VPIX Medical's solutions are primarily marketed within South Korea and are relevant to a global audience, addressing critical needs in surgical pathology and cancer treatment.

The revenue model of VPIX Medical revolves around partnerships and product sales structured around their advanced medical technologies. The company engages directly with healthcare institutions, providing its cCeLL platform and associated clinical imaging solutions under a business-to-business model. Transactions involve one-time equipment sales or ongoing service agreements, which may include maintenance and software updates. Pricing structures align with the value provided by the technology, reflecting the high demand for accurate intraoperative diagnostic tools.

VPIX Medical's revenue is expected to derive from both initial sales of its flagship products and potential subscription-based services for software and support, ensuring continued engagement with their client base in the medical field. In August 2025, VPIX Medical, Inc. raised KRW 9. 5 billion in venture funding to support its growth initiatives.

The company plans to enhance its product offerings, focusing on new developments in the cCeLL platform and other imaging solutions. VPIX Medical is targeting expansion into new markets, particularly in Asia and North America, by 2026, leveraging the recent funding to facilitate this market entry and further research and development.